89 related articles for article (PubMed ID: 18841282)
1. Cardiovascular risk factors in patients at high risk of atherothrombosis: what can be learned from registries?
Goto S
Thromb Haemost; 2008 Oct; 100(4):611-3. PubMed ID: 18841282
[No Abstract] [Full Text] [Related]
2. Baseline characteristics of patients with cerebrovascular disease in the REACH registry: the Spanish contribution.
Suárez C;
Cerebrovasc Dis; 2007; 24 Suppl 1():89-95. PubMed ID: 17971643
[TBL] [Abstract][Full Text] [Related]
3. Effects of adherence to guidelines for the control of major cardiovascular risk factors on outcomes in the REduction of Atherothrombosis for Continued Health (REACH) Registry Europe.
Cacoub PP; Zeymer U; Limbourg T; Baumgartner I; Poldermans D; Röther J; Bhatt DL; Steg PG;
Heart; 2011 Apr; 97(8):660-7. PubMed ID: 21357372
[TBL] [Abstract][Full Text] [Related]
4. The year in atherothrombosis.
Sanz J; Moreno PR; Fuster V
J Am Coll Cardiol; 2007 Apr; 49(16):1740-9. PubMed ID: 17448377
[No Abstract] [Full Text] [Related]
5. The year in atherothrombosis.
Sanz J; Moreno PR; Fuster V
J Am Coll Cardiol; 2009 Apr; 53(15):1326-37. PubMed ID: 19358949
[No Abstract] [Full Text] [Related]
6. Atherothrombotic comorbidity in the rheumatic diseases. The evidence becomes clearer. What should clinicians do?
Del Rincón I
Arthritis Rheum; 2009 Oct; 61(10):1284-6. PubMed ID: 19790116
[No Abstract] [Full Text] [Related]
7. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis.
Goto S; Bhatt DL; Röther J; Alberts M; Hill MD; Ikeda Y; Uchiyama S; D'Agostino R; Ohman EM; Liau CS; Hirsch AT; Mas JL; Wilson PW; Corbalán R; Aichner F; Steg PG;
Am Heart J; 2008 Nov; 156(5):855-63, 863.e2. PubMed ID: 19061698
[TBL] [Abstract][Full Text] [Related]
8. [Atherothrombosis: an excessively globalizing concept?].
Castillo J; Blanco M
Med Clin (Barc); 2009 Sep; 132 Suppl 2():2-4. PubMed ID: 19631830
[TBL] [Abstract][Full Text] [Related]
9. Polyvascular atherosclerotic disease: recognizing the risks and managing the syndrome.
Yakubov S
Curr Med Res Opin; 2009 Nov; 25(11):2631-41. PubMed ID: 19769467
[TBL] [Abstract][Full Text] [Related]
10. Drug treatment and cost of cardiovascular disease in Australia.
Ademi Z; Liew D; Chew D; Conner G; Shiel L; Nelson M; Soman A; Steg G; Bhatt DL; Reid C;
Cardiovasc Ther; 2009; 27(3):164-72. PubMed ID: 19689615
[TBL] [Abstract][Full Text] [Related]
11. Prevalence, awareness and treatment of cardiovascular risk factors in patients at high risk of atherothrombosis in Japan.
Yamazaki T; Goto S; Shigematsu H; Shimada K; Uchiyama S; Nagai R; Yamada N; Matsumoto M; Origasa H; Bhatt DL; Steg PG; Ikeda Y;
Circ J; 2007 Jul; 71(7):995-1003. PubMed ID: 17587702
[TBL] [Abstract][Full Text] [Related]
12. Psoriasis and atherothrombotic diseases: disease-specific and non-disease-specific risk factors.
Gisondi P; Girolomoni G
Semin Thromb Hemost; 2009 Apr; 35(3):313-24. PubMed ID: 19452407
[TBL] [Abstract][Full Text] [Related]
13. [Subclinical and clinical manifestations of atherosclerosis in antiphospholipid syndrome].
Reshetniak TM; Seredavkina nV; Mach ES; Aleksandrova EN; Novikov AA; Cherkasova MV; Nasonov EL
Ter Arkh; 2008; 80(10):60-7. PubMed ID: 19105418
[TBL] [Abstract][Full Text] [Related]
14. The burden of peripheral artery disease and the role of antiplatelet therapy.
Aronow H; Hiatt WR
Postgrad Med; 2009 Jul; 121(4):123-35. PubMed ID: 19641278
[TBL] [Abstract][Full Text] [Related]
15. Increased prevalence of hyperhomocysteinemia in cervical artery dissection causing stroke: a case-control study.
Benninger DH; Herrmann FR; Georgiadis D; Kretschmer R; Sarikaya H; Schiller A; Baumgartner RW
Cerebrovasc Dis; 2009; 27(3):241-6. PubMed ID: 19176957
[TBL] [Abstract][Full Text] [Related]
16. Classic risk factors for atherosclerosis are not major determinants for location of extracranial or intracranial cerebral atherosclerosis.
Kim YD; Choi HY; Jung YH; Nam CM; Yang JH; Cho HJ; Nam HS; Lee KY; Heo JH
Neuroepidemiology; 2009; 32(3):201-7. PubMed ID: 19169042
[TBL] [Abstract][Full Text] [Related]
17. [Inflammation and atherothrombosis. Premature vascular injury. Diagnostic and therapeutic options for primary prevention].
Ortiz Arduán A; Ruiz Ortega M; Cases Amenós A
Nefrologia; 2008; 28 Suppl 3():23-7. PubMed ID: 19018734
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk associated with interruption of antiplatelet and oral anticoagulation therapy.
Ferreira JS; Gil VM
Rev Port Cardiol; 2009; 28(7-8):845-58. PubMed ID: 19894663
[TBL] [Abstract][Full Text] [Related]
19. REACH: from registry to harmonization.
Ferrières J
Arch Cardiovasc Dis; 2008 Feb; 101(2):77-8. PubMed ID: 18398389
[No Abstract] [Full Text] [Related]
20. A Translational Medicine perspective of the development of torcetrapib: Does the failure of torcetrapib development cast a shadow on future development of lipid modifying agents, HDL elevation strategies or CETP as a viable molecular target for atherosclerosis? A case study of the use of biomarkers and Translational Medicine in atherosclerosis drug discovery and development.
Zhao L; Jin W; Rader D; Packard C; Feuerstein G
Biochem Pharmacol; 2009 Aug; 78(4):315-25. PubMed ID: 19539799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
